STOCK TITAN

HYPERFINE - HYPR STOCK NEWS

Welcome to our dedicated page for HYPERFINE news (Ticker: HYPR), a resource for investors and traders seeking the latest updates and insights on HYPERFINE stock.

Overview of Hyperfine Inc (HYPR)

Hyperfine Inc is a pioneering medical device company transforming diagnostic imaging with its innovative Swoop portable MR imaging system. This ultra-low-field, portable MRI solution offers clinicians the ability to obtain high-quality brain images directly at the patient’s bedside, addressing challenges posed by traditional, immobile MRI systems. With a design that allows the device to plug into standard electrical outlets and be controlled via an Apple iPad, Hyperfine provides an agile imaging solution that is both cost-effective and efficient.

Core Business Areas and Technology

At the heart of Hyperfine’s operations is the mission to make magnetic resonance imaging accessible to every patient regardless of location. The company’s core business is centered on:

  • Device Sales: Offering the Swoop system as a practical alternative to fixed, conventional MRI units, which are often expensive and limited to specific facilities.
  • Service Subscriptions: Bundled offerings that include maintenance, software updates, and additional support, ensuring streamlined operations and an integrated user experience.

Utilizing ultra-low magnetic field technology, the Swoop system is designed for rapid deployment in various clinical settings such as neurointensive care, emergency departments, pediatrics, and more. This approach not only supports critical decision-making with fast turnaround imaging but also complements conventional MRI systems by extending imaging capabilities to underserved environments.

Market Position and Competitive Landscape

Hyperfine Inc has established a unique niche in the healthcare technology market. Its strategic positioning as a provider of accessible and portable MRI solutions differentiates it in an industry traditionally dominated by fixed, high-cost imaging machines. The streamlined training process—where new users can achieve operational competence within a short time frame—underscores Hyperfine’s commitment to improving clinical workflow and efficiency. Moreover, the company’s ability to deliver diagnostic imaging to multiple care sites positions it strategically in an expanding market segment concerned with patient-centric, mobile imaging solutions.

Technology and Clinical Impact

Key to Hyperfine’s success is its innovative approach to MR imaging. The Swoop system leverages portable MRI and diagnostic imaging technologies to provide rapid and actionable insights during critical patient care. By facilitating near-instant image availability, it bolsters the capacity for timely clinical interventions. The ease of integration into existing clinical settings, including its simple plug-and-play nature and intuitive interface, has allowed for a broader adaptation by medical professionals who previously faced the logistical hurdles of conventional imaging modalities.

Operational Excellence and Service Model

The company’s revenue model is built on both hardware sales and recurring service subscriptions. This dual approach not only supports the initial acquisition of the imaging system but also ensures continuous improvements and maintenance through periodic service contracts. Hyperfine’s service model is designed to enhance device longevity and performance, solidifying the system’s place as a dependable clinical asset. The emphasis on ease of use—evidenced by a brief training period—further reflects the company’s commitment to operational excellence.

Clinical Relevance and Safety

Hyperfine’s imaging system has been rigorously designed to align with clinical requirements, delivering safe and effective imaging that meets regulatory standards. By focusing on bedside accessibility and image clarity, the company addresses a critical gap in healthcare delivery, particularly in emergency and intensive care situations where time is a crucial factor. The ability to generate images quickly, while ensuring ease of use and patient safety, underscores the technological sophistication underlying the Swoop system.

Conclusion

In summary, Hyperfine Inc (HYPR) is at the forefront of a shift in the diagnostic imaging landscape. By offering a portable, efficient, and user-friendly MRI solution, the company addresses longstanding limitations in access and timely imaging. Its diversified revenue streams through device and subscription sales demonstrate a robust business model tailored to modern healthcare needs. The company’s clear focus on operational excellence, technological innovation, and clinical efficiency makes it a significant entity in the evolving field of medical diagnostics.

News
Rhea-AI Summary

Hyperfine (Nasdaq: HYPR) participated in the 2024 ASNR Annual Meeting held in Las Vegas from May 18-22, 2024. The event highlighted the use of the Swoop® Portable MR Imaging® system, particularly for Alzheimer's care. Presenters emphasized the critical role of MRI in diagnosing and managing Alzheimer's disease and the potential of portable MR imaging to fill existing gaps in diagnostic capabilities. Sessions focused on the importance of monitoring amyloid-related imaging abnormalities (ARIA) for safe Alzheimer’s treatments. Attendees expressed significant enthusiasm for the Swoop® system’s benefits in clinical settings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
none
-
Rhea-AI Summary

Hyperfine (Nasdaq: HYPR) announced its Q1 2024 financial results on May 13, 2024. The company reported $3.30 million in revenue, a 25% increase from Q1 2023, and sold 13 Swoop® systems. Gross margin improved to $1.35 million. R&D expenses were $5.57 million, and SG&A expenses dropped to $6.43 million. Net loss decreased to $9.85 million ($0.14 per share) from $12.16 million ($0.17 per share) in Q1 2023. Key milestones include starting the CARE PMR Alzheimer’s study, enrolling over 100 patients in the ACTION PMR stroke study, and launching the 8th-gen AI-powered software. Full-year 2024 revenue is expected to be $12-$15 million with a $40 million cash burn.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.14%
Tags
-
Rhea-AI Summary

Hyperfine, Inc. (Nasdaq: HYPR) has appointed distributors in France, the UK, and Italy to expand the market reach of its portable MR brain imaging system, Swoop®. The company has obtained CE certification and UKCA certification for its latest hardware and AI-powered software. The move aims to meet the global demand for accessible MR brain imaging, with a focus on Alzheimer's disease and acute stroke applications. Enrico Barini joins as International Business Development Director to lead the European market expansion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
management
Rhea-AI Summary

Hyperfine, Inc. (Nasdaq: HYPR) will announce its first quarter 2024 financial results on May 13, 2024. The company, known for its FDA-cleared portable MR brain imaging system, the Swoop® system, will host a conference call on the same day. The event can be accessed via the Investors page of Hyperfine, Inc.'s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
-
Rhea-AI Summary
Hyperfine, Inc. (HYPR) presented seventeen abstracts at the ISMRM annual meeting showcasing the potential of their portable MR imaging system, Swoop®, in aiding physicians with screening and monitoring for Alzheimer’s and multiple sclerosis biomarkers. The company aims to revolutionize brain imaging with their FDA-cleared technology, demonstrating its effectiveness across various clinical conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
none
-
Rhea-AI Summary
Hyperfine, Inc. (Nasdaq: HYPR) enrolls first Alzheimer's patients in CARE PMR study to assess the clinical utility of Swoop® Portable MR Imaging® system in detecting ARIA events in patients receiving amyloid-targeting therapy. The study aims to simplify workflow and improve care efficiency in Alzheimer's treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.08%
Tags
none
Rhea-AI Summary
Hyperfine, Inc. (HYPR) reported strong growth in 2023, achieving $11.03 million in revenues, up 62% from 2022. The company sold 37 Swoop® systems in 2023, with a net loss of $44.24 million. Hyperfine received multiple certifications, launched new programs, and reduced cash burn to extend cash runway. Fourth quarter 2023 revenues were $2.69 million, up 89% from the previous year. The company sold seven Swoop® systems in Q4 2023, with a net loss of $10.68 million. Management expects 2024 revenue to reach $12 to $15 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.62%
Tags
-
Rhea-AI Summary
Hyperfine, Inc. (HYPR) showcases the first FDA-cleared portable MR brain imaging system to The Princess Royal, highlighting its use in testing MR access disparities in low- and medium-resource countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.66%
Tags
none
-
Rhea-AI Summary
Hyperfine, Inc. (HYPR) will report financial results for Q4 and full year 2023 on March 21, 2024. The company, known for its portable MR brain imaging system, Swoop®, has redefined brain imaging technology. The conference call will be hosted by management at 1:30 p.m. PT / 4:30 p.m. ET. Investors can access the live webcast on Hyperfine's Investors page.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Hyperfine, Inc. (HYPR) to present at Oppenheimer Healthcare MedTech & Services Conference with a focus on their FDA-cleared portable MR brain imaging system, the Swoop® system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.6%
Tags
conferences

FAQ

What is the current stock price of HYPERFINE (HYPR)?

The current stock price of HYPERFINE (HYPR) is $0.6993 as of April 15, 2025.

What is the market cap of HYPERFINE (HYPR)?

The market cap of HYPERFINE (HYPR) is approximately 56.0M.

What is Hyperfine Inc and what does it do?

Hyperfine Inc is a medical device company that develops and markets the Swoop portable MR imaging system. It provides high-quality brain images at the patient’s bedside, leveraging ultra-low-field MRI technology to enhance diagnostic access.

How does the Swoop system differ from conventional MRI machines?

The Swoop system is designed for portability and cost-effectiveness, allowing it to be used directly at the patient’s bedside. It operates on a lower magnetic field strength and offers rapid image availability compared to traditional, fixed MRI units.

What revenue streams support Hyperfine Inc’s business model?

Hyperfine Inc generates revenue through direct device sales and recurring service subscriptions that include maintenance, software updates, and bundled service offerings for its portable imaging systems.

In which clinical settings is the Swoop system particularly useful?

The Swoop system is beneficial in environments such as neurointensive care units, emergency departments, and pediatrics, where rapid bedside imaging can facilitate prompt diagnostic decision-making.

How does Hyperfine enhance clinical workflow with its technology?

By providing a portable imaging solution that requires minimal training and offers swift image results, the Swoop system streamlines the imaging process. This allows clinicians to integrate advanced diagnostic capabilities seamlessly into their routine patient care.

What makes Hyperfine’s approach to MRI technology innovative?

Hyperfine’s innovation lies in its ability to deliver high-quality imaging without the infrastructure demands of traditional MRI systems. Its use of portable, ultra-low-field technology redefines accessibility and provides a user-friendly, cost-effective alternative for diagnostic imaging.

How does the Swoop system support patient-centered care?

The system’s mobility allows it to be used wherever patients are located, eliminating the need to transport patients to fixed imaging centers. This accessibility promotes faster diagnosis and treatment, especially in critical care settings.

How is the training process for the Swoop system structured?

The Swoop system is designed for operational simplicity, with clinicians becoming proficient in its operation and navigation within a short duration. This ease of training supports its integration into various clinical environments smoothly.
HYPERFINE

Nasdaq:HYPR

HYPR Rankings

HYPR Stock Data

56.04M
57.32M
8.7%
22%
2.61%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
GUILFORD